Home > Insider Trading > Filing (0001225208-10-020784)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1405197	Talecris Biotherapeutics Holdings Corp.	TLCR	Pharmaceutical Preparations (2834)	202533768

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1472096	Bruce Nogales	4101 Research Commons 79 T.w. Alexander Drive Research Triangle Park NC 27709	Sr. Vp & Gm, Plasma Resources	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-09-10	7,070	$1.39	12,991	No	4	M	Direct
Common Stock	Disposition	2010-09-10	7,070	$22.95	5,921	No	4	S	Direct
Common Stock	Acquisiton	2010-09-13	18,370	$1.39	24,291	No	4	M	Direct
Common Stock	Disposition	2010-09-13	18,370	$22.96	5,921	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Options (right to buy)	Disposition	2010-09-10	7,070	$1.39	7,070	$1.39
Common Stock	Options (right to buy)	Disposition	2010-09-13	18,370	$1.39	18,370	$1.39

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,370		2015-11-10	No	4	M	Direct
0		2015-11-10	No	4	M	Direct

Footnotes

The transaction reported was effected purusant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2010.
The number of shares reported consists of restricted share units representing the right to receive 5,921 shares of the Issuers common stock that will vest in three equal annual installments beginning April 1, 2011, as detailed in a restricted share unit award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.95 to $22.975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The option is fully vested and immediately exercisable.